Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus

BACKGROUND: The relationship between cell-bound complement activation products (CB-CAPs: EC4d, EC3d), anti-C1q, soluble complement C3/C4 and disease activity in systemic lupus erythematosus (SLE) was evaluated. METHODS: Per protocol, at baseline all SLE subjects enrolled in this longitudinal study p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lupus Sci Med
Main Authors: Buyon, Jill, Furie, Richard, Putterman, Chaim, Ramsey-Goldman, Rosalind, Kalunian, Kenneth, Barken, Derren, Conklin, John, Dervieux, Thierry
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2016
Assuntos:
Biomarker Studies
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5051407/
https://ncbi.nlm.nih.gov/pubmed/27752336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2016-000165
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares